What is William Blair’s Forecast for VRTX FY2025 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at William Blair raised their FY2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a report issued on Tuesday, May 6th. William Blair analyst M. Minter now forecasts that the pharmaceutical company will post earnings per share of $16.20 for the year, up from their previous forecast of $15.83. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ FY2026 earnings at $18.47 EPS.

Several other equities research analysts have also recently commented on the company. Wells Fargo & Company cut Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective on the stock. in a research report on Thursday, January 30th. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Wolfe Research cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday. Bank of America increased their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a report on Monday, March 31st. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $503.00 price objective (down previously from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday. Thirteen equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $515.04.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $425.30 on Friday. The stock has a market capitalization of $109.34 billion, a PE ratio of -193.32, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. The stock’s 50 day simple moving average is $488.74 and its 200 day simple moving average is $465.90. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same period last year, the firm posted $4.76 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Capital World Investors lifted its position in Vertex Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock valued at $11,406,667,000 after purchasing an additional 1,514,993 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 23,491,161 shares of the pharmaceutical company’s stock valued at $11,388,985,000 after acquiring an additional 232,873 shares during the last quarter. Capital Research Global Investors increased its stake in Vertex Pharmaceuticals by 15.8% during the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after acquiring an additional 1,426,746 shares during the last quarter. Wellington Management Group LLP raised its position in Vertex Pharmaceuticals by 23.3% during the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock valued at $2,382,407,000 after purchasing an additional 1,117,214 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Vertex Pharmaceuticals by 17.2% in the 1st quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company’s stock valued at $2,454,373,000 after purchasing an additional 744,680 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Ourania Tatsis sold 244 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,315 shares of company stock valued at $2,121,012 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.